文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

大体积脑转移瘤术后瘤腔3次立体定向放射外科剂量递增1/2期试验

Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-14

该1/2期剂量递增试验评估大体积脑转移瘤术后瘤腔3次立体定向放射外科的最大耐受剂量。2009至2014年纳入48例可评估患者,剂量递增至33 Gy未达最大耐受剂量;33 Gy组1-4级放射性坏死发生率为58%,2臂中较大体积组6例中83%出现任何级别坏死。作者认为2-3 cm靶区27-30 Gy、3-4 cm靶区27 Gy可能提供毒性/肿瘤控制的较优平衡,33 Gy保留用于<3 cm的瘤腔。

要点

  • 48例可评估患者中仅1例(2%)发生急性3级毒性,剂量递增至33 Gy未达最大耐受剂量。
  • 33 Gy剂量水平全部12例任何级别坏死发生率为58%,较大体积2臂6例中为83%。
  • 30 Gy时2臂发生3-4级坏死比例为33%。

核心结论

  • 3-4级毒性发生率为8%,剂量递增至3次33 Gy未达到最大耐受剂量。
  • 33 Gy水平1-4级放射性坏死发生率为58%,2臂在30 Gy时3-4级坏死发生率为33%。
  • 作者认为2-3 cm靶区3次27-30 Gy、3-4 cm靶区27 Gy可能提供毒性/肿瘤控制的较优平衡;33 Gy保留用于<3 cm且肿瘤控制可能受益于更高剂量的瘤腔。

研究设计与样本

  • 本研究为3次立体定向放射外科治疗脑转移瘤术后瘤腔的剂量递增1/2期试验。
  • 患者按放射外科治疗体积分为2臂:1臂为4.2-14.1 cm3(约相当于直径2-3 cm球体),2臂为14.2-33.5 cm3(约相当于直径3-4 cm球体)。
  • 剂量递增水平为3次连续日照射24、27、30、33 Gy,采用6+6试验设计,每个剂量水平6例患者。
  • 剂量限制毒性定义为急性(放射外科后30天内)3-5级中枢神经系统毒性和/或后续任何时间点发生的晚期3-5级放射性坏死。
  • 最大耐受剂量定义为6例中0-1例或12例中0-3例发生剂量限制毒性的最高剂量。

主要发现

  • 1例(2%)患者发生急性3级毒性,剂量递增继续至33 Gy,未达到最大耐受剂量。
  • 48例患者中14例(29%)发生1-4级晚期放射性坏死:1级4例(8%)、2级6例(13%)、3级2例(4%)、4级2例(4%)。
  • 33 Gy剂量水平全部12例任何级别坏死发生率为58%,较大体积2臂6例中为83%;较小体积1臂靶区未发生3-4级坏死。
  • 中位总生存期为24个月(95%CI 18-35),1年累积发生率:局部进展10%(95%CI 3.8-21)、颅内远处进展48%(95%CI 33-61)、放射性坏死13%(95%CI 5-24)。
  • 结节性脑膜病发生于15%(7/48)的患者。

关键数值与推荐

  • 剂量递增水平为3次连续日照射24、27、30、33 Gy。
  • 最大耐受剂量定义为6例中0-1例或12例中0-3例发生剂量限制毒性的最高剂量,本研究未达到。
  • 作者认为2-3 cm靶区3次27-30 Gy、3-4 cm靶区27 Gy可能提供毒性/肿瘤控制的较优平衡;33 Gy保留用于<3 cm瘤腔。

临床怎么用

  • 作者认为2-3 cm靶区3次27-30 Gy、3-4 cm靶区27 Gy可能提供毒性/肿瘤控制的较优平衡。
  • 作者认为3次33 Gy保留用于<3 cm且肿瘤控制可能受益于更高剂量的瘤腔。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a dose escalation trial of hypofractionated stereotactic radiosurgery (SRS) to determine the maximum tolerated dose (MTD) of 3-fraction SRS for brain metastases resection cavities. METHODS AND MATERIALS: Following surgical resection of a brain metastasis, patients were enrolled by SRS treatment volume onto 2 arms: arm 1 = 4.2-14.1 cm3, approximating a 2 to 3 cm diameter sphere, and arm 2 = 14.2-33.5 cm3 or a 3 to 4 cm sphere equivalent. Dose escalation levels were 24, 27, 30, and 33 Gy in 3 consecutive-day fractions, with 6 patients at each dose level in a 6 + 6 trial design. Dose-limiting toxicity was defined as either acute (within 30 days of SRS) grade 3 to 5 central nervous system toxicity and/or late grade 3 to 5 radiation necrosis occurring at any subsequent timepoint. The MTD was defined as the highest dose where 0 to 1 out of 6 or 0 to 3 out of 12 had a dose-limiting toxicity. RESULTS: From 2009 to 2014, 48 evaluable patients were enrolled. One (2%) patient had acute G3 toxicity; dose escalation proceeded to 33 Gy. No MTD was reached. Overall, 14 (29%) of 48 patients had G1-4 late radiation necrosis; G1 in 4 (8%), G2 in 6 (13%), G3 in 2 (4%), and G4 in 2 (4%). At the 33 Gy dose level, any grade necrosis was 58% in all 12 patients, 83% in the 6 patients on the larger volume arm 2; no G3-4 necrosis occurred in smaller arm 1 targets. With a median overall survival of 24 months (95% CI, 18-35), the 1-year cumulative incidence rates were: 10% (95% CI, 3.8-21) for local progression, 48% (95% CI, 33-61) for distant intracranial progression, and 13% (95% CI, 5-24) for radiation necrosis. Nodular meningeal disease occurred in 15% (7 of 48) of patients. CONCLUSIONS: Grade 3 to 4 toxicity was 8% and no MTD was reached with dose escalation to 33 Gy in 3 fractions. However, with a 58% incidence of G1-4 radiation necrosis at the 33 Gy level and 33% G3-4 necrosis at 30 Gy on arm 2, a 3-fraction dose of 27-30 Gy for targets 2 to 3 cm and 27 Gy for targets 3 to 4 cm may provide the optimal balance between toxicity and tumor control. A dose of 33 Gy is reserved for cavities <3 cm where tumor control may benefit from higher doses.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Klebaner D, Pollom EL, Rahimy E, et al. Phase 1/2 Dose Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases. Int J Radiat Oncol Biol Phys. 2025. PMID: 40089071. doi:10.1016/j.ijrobp.2025.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。